iSpecimen
NASDAQ: ISPCWoburn, US · Founded 2009 · Delaware corporation · 17 employees on LinkedIn
iSpecimen operates an online marketplace that connects medical researchers to a global network of biospecimen providers, offering access to human biospecimens such as diagnostic remnant, banked, and prospective collections. The platform serves the biospecimen procurement needs of researchers in the life sciences and healthcare research industry.
Founders & leadership
iSpecimen was founded in 2009 by Jill Mullan and Christopher Ianelli.
JM
Jill MullanCo-founder
CI
Christopher IanelliinCo-founderBefore founding his current company, Christopher Ianelli spent seven years working in digital agencies as a consultant and software developer. He is the CEO of Storyblok, a headless content management system that lets developers build flexible components which marketers manage through a visual editor, with published content delivered via API across websites, mobile, and other digital platforms.
KF
Katharyn FieldPresident
RB
Robert Bradley LimExecutive
BC
Bruce CrannaNamed on SEC filing
Board
GS
George SchollBoard director
AR
Andrew RossBoard director
SY
Siyun YangBoard director
AD
Avtar DhaliwalBoard director
AL
Anthony LauBoard director
Reported raises · per SEC filings
Form D private placements$40.6M disclosed across 7 rounds · 2014–2026
▶$2.5MraisedMay 2026 · 2 investors · OtherRule 506(b)
▶$2.5MraisedMay 2026 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony LauDirector
- Arphing (Tommy) LeeDirector
- Avtar DhaliwalDirector
- Katharyn FieldExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $100K
- Placement agents
- E.F. Hutton & Co.
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedJan 2026 · 3 investors · OtherRule 506(b)
▶$5.5MraisedJan 2026 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Siyun YangDirector
- Arphing (Tommy) LeeDirector
- Anthony LauDirector
- Katharyn FieldExecutive Officer
- Avtar DhaliwalDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- Sales commissions
- $220K
- Placement agents
- E.F. Hutton & Co.
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedAug 2025 · 4 investors · OtherRule 506(b)
▶$1.8MraisedAug 2025 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Siyun YangDirector
- Avtar DhaliwalDirector
- Katharyn FieldExecutive Officer
- Anthony LauDirector
- Robert Bradley LimExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Sales commissions
- $70K
- Placement agents
- Westpark Capital, Inc
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21MraisedDec 2021 · 4 investors · Other Health CareRule 506(b)
▶$21MraisedDec 2021 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin BielakExecutive Officer
- Steven GullansDirector
- John L. Brooks IIIDirector
- Margaret H. LawrenceDirector
- Tracy CurleyExecutive Officer
- Andrew RossDirector
- George SchollDirector
- Jill MullanExecutive Officer, Director
- Christopher J. IanelliExecutive Officer, Director
- Offering amount
- $21M
- Amount sold
- $21M
- Sales commissions
- $1.3M
- Placement agents
- ThinkEquity LLC
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$800KraisedAug 2018 · 3 investors · Other Health CareRule 506(b)
▶$800KraisedAug 2018 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Christopher J. IanelliExecutive Officer, Director
- Jill MullanDirector
- Andrew RossDirector
- George SchollDirector
- Offering amount
- $4M
- Amount sold
- $800K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedMar 2017 · 1 investors · Other Health CareRule 506(b)
▶$500KraisedMar 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- George SchollDirector
- Andrew RossDirector
- Jill MullanExecutive Officer, Director
- Christopher IanelliExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $500K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.6MraisedSep 2014 · 13 investors · Other Health CareRule 506(b)
▶$8.6MraisedSep 2014 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jill MullanExecutive Officer, Director
- Christopher IanelliExecutive Officer, Director
- Andrew RossDirector
- George SchollDirector
- Bruce CrannaExecutive Officer
- Offering amount
- $8.6M
- Amount sold
- $8.6M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Precision For Medicine50 shared keywordsPrecision for Medicine is a contract research organization that provides clinical trial management and regulatory support for drug development programs, including oncology, hematology, cell and gene therapy, CAR-T, and radiopharmaceutical trials. It serves pharmaceutical and biotech sponsors running multinational Phase I–IV studies.
Labcorp38 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Companies competing with iSpecimen for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
iSpecimen (NASDAQ: ISPC) plans $4M common stock and pre-funded warrant salestocktitan.net · Jun 2026
iSpecimen Regains Nasdaq Compliance and Raises New Capital - TipRanks.comtipranks.com · May 2026Frequently asked questions
- What does iSpecimen do?
- iSpecimen operates an online marketplace that connects medical researchers to a global network of biospecimen providers, offering access to human biospecimens such as diagnostic remnant, banked, and prospective collections. The platform serves the biospecimen procurement needs of researchers in the life sciences and healthcare research industry.
- Who founded iSpecimen?
- iSpecimen was founded by Jill Mullan, Christopher Ianelli in 2009.
- How much funding has iSpecimen raised?
- iSpecimen has disclosed $40.6M raised across 7 rounds.
- Where is iSpecimen headquartered?
- iSpecimen is headquartered in Woburn, US.